Orchard Therapeutics plc (ORTX)
Jan 24, 2024 - ORTX was delisted (reason: acquired by Kyowa Kirin)
16.70
0.00 (0.00%)
Last trade price

Orchard Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year
20222021202020192018 2017 - 2016
Revenue
22.661.682.62.512.08
Upgrade
Revenue Growth (YoY)
1252.54%-35.45%3.26%21.05%-
Upgrade
Cost of Revenue
6.770.230.860.810.42
Upgrade
Gross Profit
15.881.451.741.711.65
Upgrade
Selling, General & Admin
49.1354.9164.9957.2231.37
Upgrade
Research & Development
93.8586.9893.73117.36205.32
Upgrade
Operating Expenses
142.97141.88158.72174.58236.69
Upgrade
Operating Income
-127.09-140.43-156.98-172.87-235.03
Upgrade
Interest Expense / Income
3.082.52.331.540
Upgrade
Other Expense / Income
22.870.83-6.6-8.75-5.51
Upgrade
Pretax Income
-153.03-143.76-152.71-165.66-229.53
Upgrade
Income Tax
-2.370.83-0.73-2.240.97
Upgrade
Net Income
-150.66-144.58-151.98-163.42-230.5
Upgrade
Shares Outstanding (Basic)
128124999323
Upgrade
Shares Outstanding (Diluted)
128124999323
Upgrade
Shares Change
3.24%24.65%6.66%313.31%154.25%
Upgrade
EPS (Basic)
-11.80-11.70-15.30-17.50-102.20
Upgrade
EPS (Diluted)
-11.80-11.70-15.30-17.50-102.20
Upgrade
Free Cash Flow
-74.54-127.23-137.07-170.5-101.57
Upgrade
Free Cash Flow Per Share
-5.82-10.26-13.78-18.29-45.02
Upgrade
Gross Margin
70.11%86.51%66.97%67.97%79.67%
Upgrade
Operating Margin
-560.97%-8384.06%-6049.25%-6879.15%-11321.34%
Upgrade
Profit Margin
-665.02%-8631.88%-5856.61%-6503.06%-11102.84%
Upgrade
Free Cash Flow Margin
-329.00%-7595.76%-5281.93%-6784.64%-4892.49%
Upgrade
EBITDA
-147.21-138.93-148.38-162.45-228.33
Upgrade
EBITDA Margin
-649.81%-8294.45%-5717.84%-6464.35%-10998.36%
Upgrade
Depreciation & Amortization
2.742.3321.681.2
Upgrade
EBIT
-149.96-141.26-150.38-164.12-229.53
Upgrade
EBIT Margin
-661.91%-8433.37%-5795.07%-6531.00%-11056.12%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).